Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03711162 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
A Phase 3 study, sponsored by Lakefront Biotherapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 525
- Enrollment target
NCT03711162: Clinical Trial Phase 3 study, sponsored by Lakefront Biotherapeutics.
NCT03711162 is a Phase 3 study that was terminated before completion, run by Lakefront Biotherapeutics. The registered enrollment target is 525 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03711162, a Phase 3 study, was terminated before completion, sponsored by Lakefront Biotherapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 525 participants
- Enrollment target
Study Summary
The main purpose of this study was to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study also investigated how well GLPG1690 is tolerated (for example if you got any side effects while on study drug).
Interventions
- DRUG Placebo
- DRUG GLPG1690
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 525 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2021-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03711162
The ClinicalTrials.gov registry entry for NCT03711162 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 525 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lakefront Biotherapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03711162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03711162 about?
NCT03711162 is a clinical study titled "A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care". The main purpose of this study was to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study also investigated how well GLPG1690 is tolerated (for example if you got any side effects while on study drug).
What is the current status of trial NCT03711162?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 525 participants. The study started on 2018-11-28. Estimated completion is 2021-03-30.
What interventions are being tested in trial NCT03711162?
The interventions under investigation include: Placebo (DRUG), GLPG1690 (DRUG).
Who is sponsoring clinical trial NCT03711162?
This trial is sponsored by Lakefront Biotherapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.